Monitor for any appeal by Stryker/Inari to the Federal Circuit and for the lifting of the stay in the related district court litigation. The invalidation of this patent, combined with prior FWDs on related patents, weakens Inari's IP moat against competitors like Imperative Care.
Price Chart
Executive Summary
The PTAB issued a Final Written Decision in IPR2025-00989, finding all challenged claims (1–8 and 12–19) of Inari Medical's '291 patent (owned by Stryker Corp via subsidiary) unpatentable. This is a loss for Stryker/Inari, as the patent covering hemostasis valves used in minimally invasive surgery has been invalidated, removing a key IP barrier for petitioner Imperative Care.
PTAB Trial Details
Key Facts
- Final Written Decision in IPR2025-00989 finds all challenged claims (1–8, 12–19) of U.S. Patent 11,865,291 unpatentable
- Patent owner is Inari Medical, Inc., a wholly-owned subsidiary of Stryker Corporation (SYK)
- Petitioner is Imperative Care, Inc.
- The '291 patent covers hemostasis valves and methods of use in minimally invasive surgery
- Related district court litigation (Inari Medical v. Imperative Care, No. 24-cv-3117 N.D. Cal.) is currently stayed
- Multiple related IPRs have also resulted in Final Written Decisions finding claims unpatentable, with appeals voluntarily dismissed
- This is the 5th Final Written Decision in a series of IPRs against Inari's hemostasis valve patents, all resulting in claims being found unpatentable
Financial Impact
Not quantified in the decision; the invalidated patent covers a component of Inari's catheter-based thrombectomy systems. Stryker acquired Inari Medical for $4.9 billion in 2024. The cumulative loss of multiple patents in this family may erode competitive barriers for Inari's product line.
Risk Factors
- Further erosion of Inari's patent portfolio as multiple related IPRs remain pending
- Potential for increased competition in the thrombectomy market if competitors launch products previously blocked by these patents
- Stryker may need to rely on trade secrets or other IP to maintain competitive advantage
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-IPR2025-00989-fwd-SYK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | PTAB Trial | $297.60 | awaiting T+5 | — | $307.15 (−3.21%) |
Oct 7, 2026 18d ago | ANALYST-UPGRADE | $275.25 $282.55 | ▲ +2.65% | ▲ +2.55% | $307.15 (+11.59%) |
Oct 6, 2026 19d ago | 8-K | $278.20 $282.55 | ▲ +1.56% | ▲ +1.70% | $307.15 (+10.41%) |
Oct 6, 2026 19d ago | Press Release | $278.20 $282.55 | ▲ +1.56% | ▲ +1.70% | $307.15 (+10.41%) |
Oct 1, 2026 24d ago | Press Release | $272.96 | awaiting T+5 | — | $307.15 (+12.53%) |
Aug 31, 2026 7w ago | Press Release | $317.40 $275.39 | ▼ −13.24% | ▼ −13.32% | $307.15 (−3.23%) |
Aug 26, 2026 8w ago | Insider Cluster | $322.12 $307.99 | ▼ −4.39% | ▼ −4.66% | $307.15 (−4.65%) |
Aug 20, 2026 9w ago | Insider Cluster | $329.45 $330.69 | ▲ +0.38% | ▼ −0.10% | $307.15 (−6.77%) |
Jul 13, 2026 15w ago | Court Ruling | $311.07 $314.58 | ▲ +1.13% | ▲ +1.60% | $307.15 (−1.26%) |
Jul 9, 2026 15w ago | ANALYST-UPGRADE | $327.11 $331.20 | ▲ +1.25% | ▲ +1.38% | $307.15 (−6.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers